Gene Therapy: JCR Pharmaceuticals and Modalis Advance Research JCR Pharmaceuticals Co., Ltd. (TOKYO:4552) and Modalis Therapeutics Corporation (TOKYO:4883) have announced a major advancement in their joint research program aimed at…
Therapies: PharmaEssentia Ensures Reliable Interferon Access PharmaEssentia (TWSE: 6446), a leading global biopharmaceutical company, has reaffirmed its commitment to ensuring robust and reliable access to critical interferon therapies, particularly in…
OS Therapies Completes $6 Million Private Placement OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company specializing in cancer immunotherapy and antibody-drug conjugates, today announced the successful completion of a…
Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new cancer treatments, has announced that the U.S. Food and…
RenovoRx Expands IP Portfolio for Novel Drug-Delivery Platform RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath® delivery system, today…
Marinus Pharmaceuticals to Be Acquired by Immedica Immedica Pharma AB, a global leader in rare diseases, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company dedicated to enhancing the lives of…
Opdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo…
Tivic Health CEO’s Letter to Shareholders Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company pioneering bioelectronic medicine, has released its annual letter from the CEO to shareholders, highlighting…
Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company focused on developing innovative therapies for hearing loss disorders, has…
Anebulo Pharmaceuticals announces positive update and capital raise for Selonabant Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company focused on developing innovative treatments for acute cannabinoid-induced toxicities, has announced…
Cervical Cancer : NERLYNX® Added to NCCN Guidelines for HER2-Mutation Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on advancing cancer treatments, has announced that the National Comprehensive Cancer…
Exicure, Inc. (Nasdaq: XCUR, “Exicure” or the “Company”), today announced that its stockholders approved a second investment of $8.7 million from HiTron Systems Inc. (“HiTron”), a publicly listed company on…